en Hematology Hematology Original Article Original Article <span style="font-family:Times New Roman;"><span style="font-size:14px;"><span style="color:#0033ff;"><strong><em>Background</em></strong><em>:</em></span> Autologous hematopoietic stem cell transplantation (auto-HSCT) has become an effective treatment for a wide range of hematologic and non-hematologic diseases. Patients undergoing HSCT might require multiple platelets and red blood cell (RBC) transfusions during aplasia phase until engraftment, which could profoundly affect patients&rsquo; conditions. Identification of risk factors associated with blood product requirements could help in decreasing transfusion-related complications. We evaluated the association of disease type, pre-transplant hemoglobin level, and pre-transplant platelet count with RBC/platelet transfusion requirement after auto-HSCT.<br> <span style="color:#0033ff;"><strong><em>Methods</em></strong><em>:</em></span> In this retrospective study, 324 patients diagnosed with multiple myeloma (MM), Hodgkin disease (HD), and non-Hodgkin lymphoma (NHL) and underwent auto-HSCT were included. The associations of disease type, pre-transplant hemoglobin level, and platelet count with post-transplant packed cell and single-/random-donor platelet transfusions were evaluated.<br> <span style="color:#0033ff;"><strong><em>Results</em></strong><em>:</em></span> Our study results illustrated that the higher pre-transplant hemoglobin level significantly decreased the post-HSCT requirement for packed cell (IRR=0.81, [CI: 9.73-0.90], P=0.0001), while the pre-transplant platelet showed no significant relationship with platelet requirement after HSCT. HD was associated with increment in packed cell (IRR=2.04, [CI: 1.35-3.08], P=0.001) and single donor platelet (IRR=1.39, [CI: 1.09-1.78], P=0.008) requirement after transplant. The trends showed that a higher platelet level led to a lower need for platelet transfusion.<br> <span style="color:#0033ff;"><strong><em>Conclusion</em></strong><em>:</em></span> Pre-transplant hemoglobin level could be valuable markers for predicting post-HSCT RBC requirements and might be beneficial for better management of transfusion requirements to minimize the transfusion-related complications. Patients with HD seem to be more prone to blood product requirements post-transplant.</span></span><span dir="RTL"></span> Autologous, Hematopoietic stem cell transplantation, Hemoglobin, Platelet, Transfusion 544 550 http://caspjim.com/browse.php?a_code=A-10-1891-1&slc_lang=en&sid=1 Shabnam Tabasi tabasi,sr@gmail.com 100319475328460032127 100319475328460032127 No Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Sayeh Parkhideh drsayehparkhideh@yahoo.com 100319475328460032128 100319475328460032128 No Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Elham Roshandel elham.roshandel@gmail.com 100319475328460032129 100319475328460032129 No Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Samira Karami samira112200@gmail.com 100319475328460032130 100319475328460032130 No Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Anahita Saeedi saeedianahita8@gmail.com 100319475328460032131 100319475328460032131 No Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Ali Jabbari m.salimi.em@gmail.com 100319475328460032132 100319475328460032132 No Department of Anesthesiology and Critical Care Medicine, Golestan University of Medical Sciences (GoUMS), Head of the Clinical Research Development Center, Gorgan, Iran Abbas Hajifathali hajifathali@yahoo.com 100319475328460032133 100319475328460032133 Yes Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran